Eli Lilly and Company
LLYFull coverage—Eli Lilly and Company
LLYNew York Stock ExchangeFull coverage
Q3 fiscal 2026 edition
A free account unlocks one dossier edition a month.
Create a free accountAlready have an account? Sign in
Summary
Free to read
Eli Lilly makes medicines, and most of its revenue now comes from incretin drugs for diabetes and obesity: Mounjaro, Zepbound and the new Foundayo pill brought in 66% of revenue in the first nine months of 2026. In the third quarter revenue rose 39% to $24.4 billion, as 53% more volume more than offset 15% lower realized prices, while large charges for acquired research held reported earnings growth to 16%. What decides the business's future is how long volume keeps outrunning falling prices, as growth shifts to cheaper channels such as Medicare and markets abroad, and what replaces tirzepatide when its US patent ends, which the company estimates for 2036. Moatsight estimates revenue of about $100.7 billion and free cash flow of about $22.7 billion over the next four quarters.
In the full dossier
- Part 1In brief
- Part 2Business explainer
- Part 3Earnings
- Part 4Valuation and projections
- Part 5What changed
General research and analysis by Moatsight, not personalized investment advice. We show, you decide. Disclaimers